Analyst Ratings for [GRTS] Gritstone Oncology Inc.

10/1/24	Downgrades	Mkt Outperform Mkt Perform	X
GRTS Gritstone bio JMP Securities
2/28/24	Initiated	Mkt Outperform	X
GRTS Gritstone bio JMP Securities
$4
3/31/23	Initiated	Outperform	X
GRTS Gritstone bio Evercore ISI
3/28/23	Initiated	Buy	X
GRTS Gritstone bio B. Riley Securities
$8
10/31/22	Initiated	Overweight	X
GRTS Gritstone bio Piper Sandler
$6
8/22/22	Downgrades	Neutral Sell	X
GRTS Gritstone bio Goldman
$2
12/15/21	Resumed	Neutral	X
GRTS Gritstone bio Goldman
$15
10/15/21	Resumed	Buy	X
GRTS Gritstone bio BTIG Research
$20
1/20/21	Downgrades	Outperform Underperform	X
GRTS Gritstone Oncology Robert W. Baird
$8
7/26/19	Initiated	Outperform	X
GRTS Gritstone Oncology Robert W. Baird
$17
3/15/19	Initiated	Outperform	X
GRTS Gritstone Oncology Raymond James
3/7/19	Initiated	Buy	X
GRTS Gritstone Oncology H.C. Wainwright
$17
10/23/18	Initiated	Buy	X
GRTS Gritstone Oncology BTIG Research
$26
10/23/18	Initiated	Neutral	X
GRTS Gritstone Oncology Goldman
$18

GRTS Gritstone Oncology Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.